


What is Claimed:

1. A compound of Formula (I):



(I)

wherein:

R¹ and R² are, independently of each other:

- (i) hydrogen;
- (ii) alkyl; or
- (iii) -COR³ wherein R³ is selected from the group consisting of alkyl, amino, monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, -NHCOR^a (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), -NHCONHR^a (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and -OR^b (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R¹ and R² is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

Ar¹, Ar², Ar³, and Ar⁴ are independently selected from the group consisting of arylene, substituted arylene, and optionally substituted heteroarylene; and

L is:

- (i) alkylene;
- (ii) alkylene substituted with one, two or three substituent(s) selected from the group consisting of aryl, -CONHR⁴ (wherein R⁴ is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl, heterocyclic, substituted heterocyclic, heterocyclicalkyl, heteroarylthioalkyl, or -(CHR⁵)_{n1}-CO-(NH-Ar³-CO)_m-NH-Ar⁴-CO-NHR³ where n1 is 1 to 3, R⁵ is hydrogen or alkyl, substituted alkyl, and Ar³, m, Ar⁴, and R³ are as defined above), -CONHNHR⁶ [wherein R⁶ is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, -COR⁷, -COOR⁸ (wherein R⁷ and R⁸ are independently of each other alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, or heteroaralkyl), heteroaryl, or heteroaralkyl], -NHR⁹ (wherein R⁹ is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminoalkylcarbonyl, or heterocycliccarbonyl), and guanidino; or
- (iii) -(alkylene)_x-Z-(alkylene)_y-(Z^a)_z- wherein x, y and z are independently 0, 1, or 2 and Z and Z^a are, independently of each other, phenylene, cycloalkylene optionally fused to one or two phenylene ring(s), heterocyclene, -O-, -S-, -NR¹⁰- [wherein R¹⁰ is hydrogen, alkyl, substituted alkyl, cycloalkylcarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, -CONHR⁴, -COR⁷, -COOR⁸ (where R⁴, R⁷ and R⁸ are as defined above), -SO₂R¹¹ (where R¹¹ is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl) or -(CHR⁵)_{n2}-NH-(CO-Ar³-NH)_m-CO-Ar⁴-NHR² where n2 is 2 to 4, R⁵ is hydrogen, alkyl, or substituted alkyl, and Ar³, m, Ar⁴, and R² are as defined above], -CO-NH-, or -NH-CO-, provided that

when Z and/or Z^a is -NR¹⁰- then it is separated from another nitrogen atom by at least two carbon atoms;

or a pharmaceutically acceptable salt thereof.

5

2. The compound of Claim 1 wherein Ar¹, Ar², Ar³ and Ar⁴ are independently an optionally substituted heteroarylene.

10

3. The compound of Claim 2 wherein Ar¹, Ar², Ar³ and Ar⁴ are independently a 1-methylpyrrole that is linked to the carbonyl group at the 2-position and the amino group at the 4-position of the pyrrole ring.

4. The compound of Claim 1 wherein n and m are 0 or 1.

15

5. The compound of Claim 4 wherein Ar¹, Ar², Ar³ and Ar⁴ are independently an optionally substituted heteroarylene.

6. The compound of Claim 1 wherein R¹ and R² are independently -COR³.

20

7. The compound of Claim 6 wherein R¹ and R² are independently aminomethylcarbonyl, 1-amino-4-guanidinobutylcarbonyl, 1,4-diaminobutylcarbonyl, 1,5-diaminopentyl-carbonyl, 1-amino-5-(3,4-difluorophenylureido)pentylcarbonyl, 1-(3,4-difluoro-phenylureido)-4-guanidinobutylcarbonyl, 1-[4-(N,N-(2-chloroethyl)-aminophenyl-butanoyl)]amino-4-guanidinobutylcarbonyl, 1-amino-5-[4-(N,N-(2-chloroethyl)-aminophenyl-butanoyl)]aminopentylcarbonyl, or pyrene-1-ylmethoxy.

25

8. The compound of Claim 1 wherein L is alkylene.

30

9. The compound of Claim 8 wherein L is 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,6-hexylene, 1,8-octylene, 1,12-dodecylene, 1-methylethylene, or 1,2-hexadecylene.
- 5 10. The compound of Claim 1 wherein L is substituted alkylene.
11. The compound of Claim 10 wherein L is meso-1,2-diphenylethylene, 1-(p-nitrophenylaminocarbonyl)-1,5-pentylene, 1-(naph-2-ylaminocarbonyl)-1,5-pentylene, 1-(pentafluorophenylhydrazidocarbonyl)-1,5-pentylene, 1-(5-trifluoro-pyrimidin-2-ylhydrazidocarbonyl)-1,5-pentylene, 1-(2-pyrene-1-ylethylamino-carbonyl)-1,5-pentylene, 1-[2-(6-nitrobenzimidazol-1-ylethylaminocarbonyl)-1,5-pentylene, 1-[2-(indol-3-yl)-ethylaminocarbonyl]-1,5-pentylene, 1-[2-(5-fluoroindol-3-yl)ethylaminocarbonyl]-1,5-pentylene, 1-[2-(4-nitrophenyl)ethylaminocarbonyl]-1,5-pentylene, 1-(benzyloxycarbonyl-hydrazidocarbonyl)-1,2-ethylene, 1-(naph-1-ylaminocarbonyl)-1,5-pentylene, 1-(4-pyrene-1-ylbutylaminocarbonyl)-1,5-pentylene, 1-(2-(2-trifluoromethylquinolin-4-yl)thio-ethylaminocarbonyl)-1,5-pentylene, 1-(pentafluorophenylhydrazidocarbonyl)-1,4-butylene, 1-(4-pyrene-1-ylmethylaminocarbonyl)-1,5-pentylene, 1-(2-hydroxyethylaminocarbonyl)-1,5-pentylene, 1-(2-aminoethylaminocarbonyl)-1,5-pentylene, 1-(3-dimethylaminopropyl-aminocarbonyl)-1,5-pentylene, 1-(bis-(2-aminoethyl)aminoethylaminocarbonyl)-1,5-pentylene, 1-(N-(2-aminoethyl)aminoethylaminocarbonyl)-1,5-pentylene, 2-(amino-methylcarbonyl-amino)-1,3-propylene, or 2-(3-hydroxypyrrolidin-5-ylcarbonyl-amino)-1,3-propylene.
12. The compound of Claim 1 wherein L is $-(\text{alkylene})_x-Z-(\text{alkylene})_y-(Z^a)_z-$.
13. The compound of Claim 12 wherein L is m-xylene, p-xylene, 2,7-fluorendiyl, *bis*-(3-N-benzyloxycarbonylamino)propylene $[-(\text{CH}_2)_3-\text{N}(\text{BzOCO})-(\text{CH}_2)_3-]$, *bis*-(2-naph-2-ylsulfonylamino)ethylene $[-(\text{CH}_2)_2-\text{N}(\text{SO}_2\text{naph-2-yl})-(\text{CH}_2)_2-]$, *bis*-(2-N-3,5-dinitrophenylcarbonylamino)ethylene

[-(CH₂)₂-N(-CO-3,5-dinitrophenyl)-(CH₂)₂-], 1,3-cyclohexyl-bis-methylene [-(CH₂)-(1,3-C₆H₁₀)-(CH₂)-], 1,4-cyclohexyl-bis-methylene [-(CH₂)-(1,4-C₆H₁₀)-(CH₂)-], 4,4'-methylene-bis-1,4-cyclohexylene [-(1,4-C₆H₁₀)-(CH₂)-(1,4-C₆H₁₀)-], 1,2-cyclohexylene (1,2-C₆H₁₀-), *bis*-(2-adamantyl-1-ylcarbonylamino)ethylene, *bis*-(3-N-methylamino)propylene [-(CH₂)₃-N(-CH₃)-(CH₂)₃-], *bis*-(3-amino)propylene [-(CH₂)₃-NH-(CH₂)₃-], 1,4-piperazino- *bis*-propylene [-(CH₂)₃-(1,4-piperazino)-(CH₂)₃-], *bis*-(2-(2-aminoethyl)amino)ethylene [-(CH₂)₂-N(-(CH₂)₂NH₂)-(CH₂)₂-], and *bis*-(2-amino)ethylene [-(CH₂)₂-NH-(CH₂)₂-].

10

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 1-13, and a pharmaceutically suitable carrier.


15

15. A method for the treatment of diseases caused by pathogenic organisms, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition containing a therapeutically effective amount of a compound of Claims 1-13 and a pharmaceutically suitable carrier.

20

16. The method of Claim 15 wherein the disease is cancer.

17. A compound of the formula (II).








25

wherein R²¹ is an arylene, heteroarylene, substituted arylene or substituted heteroarylene; each R²⁰ is independently alkyl or substituted alkyl; and each R²² is independently guanidino or amidino.


18. The compound of claim 17 where in R^{21} is selected from the group consisting of 1,4-phenylene, 1,3-phenylene, 1,3-phenylene, 1,4-pyridylene, 1,3-pyridylene, 2,4-pyrimidinylene, 2,5-pyrimidinylene, 3,5-(1,2,4)-triazolene, 2,5-thiazolene, and 2,7-naphthylene; wherein said 1,4-phenylene and 1,3-phenylene are optionally substituted; and each R^{20} is independently selected from the group consisting of methyl, ethyl, propyl, isoamyl, and cyclopropylmethyl.

19. The compound of claim 18 selected from the group consisting of







193




195




197




199



201




204



and pharmaceutically acceptable salts thereof.


20. A compound of the formula (VII)




Wherein


- L is selected from the group consisting of alkylene and cycloalkylene;
 A is an amino acid side chain, and
 R^{23} is selected from the group consisting of guanidino, amino, and ornithylamino.

21. A compound of claim 20 selected from the group consisting of







177




173




169



171



170



172

and pharmaceutically acceptable salts thereof.

5

22. A compound selected from the group consisting of:

Compounds 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 77, 78, 79,

80, 81, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158. (depicted

5 on pages 17-25, and Figures 1-8).